David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Oratie prof. dr. Tuna Mutis
mrt 2019 | Immuuntherapie, Leukemie, Lymfoom, MM